Circio Holding ASA Logo

Circio Holding ASA

Developing circular RNA vector tech and immunotherapies for gene and cell therapies.

CRNA | OL

Overview

Corporate Details

ISIN(s):
NO0012858564 (+5 more)
LEI:
5967007LIEEXZXFYNS31
Country:
Norway
Address:
Vollsveien 19, 1366 Lysaker
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Circio Holding ASA is a biotechnology company developing novel circular RNA (circRNA) and immunotherapy medicines. The company's strategic focus is on its proprietary circRNA vector expression technology, designed to enhance the efficacy and safety of next-generation gene and cell therapies. Circio aims to establish a leading position in deploying circRNA for treating genetic diseases and other difficult-to-treat conditions. Its development platform, circVec, has shown the potential for substantially increased protein expression compared to conventional mRNA-based vectors. The company's pipeline includes both its circRNA gene therapy platform and clinical-stage immune-oncology candidates.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-03 08:13
Major Shareholding Notification
Corr: Atlas Holdings for CIRCIO
English 762 bytes
2025-10-30 11:02
Major Shareholding Notification
Corr: Atlas Holdings for CIRCIO
English 743 bytes
2025-10-30 08:04
Major Shareholding Notification
Atlas Holdings for CIRCIO
English 744 bytes
2025-10-23 15:23
Major Shareholding Notification
Flaggmelding fra Høse AS
Norwegian 816 bytes
2025-10-23 11:02
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-22 11:27
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-20 10:33
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-19 21:45
Share Issue/Capital Change
Circio Holding ASA Bond conversion and additional trading restrictions
English 3.7 KB
2025-10-17 16:39
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 3.0 KB
2025-10-15 11:14
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 3.0 KB
2025-10-08 07:00
Regulatory News Service
Circio presents comprehensive circVec in vivo data package demonstrating 40-fol…
English 6.2 KB
2025-10-06 12:07
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 2.8 KB
2025-10-01 16:55
Prospectus
Circio Holding ASA Approval and publication of prospectus for potential futur…
English 3.0 KB
2025-10-01 07:00
Regulatory News Service
Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025
English 3.7 KB
2025-09-09 09:53
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 2.5 KB

Automate Your Workflow. Get a real-time feed of all Circio Holding ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Circio Holding ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Circio Holding ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America
CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden
CAMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.